NextFin News - Biotech venture capital used to market itself as patient equity: money willing to absorb years of failed experiments for the chance that one drug, one platform or one clinical signal would produce outsize equity upside. That compact is changing. Across the sector, young drugmakers are relying more heavily on milestone-based rounds, royalty sales, synthetic royalty agreements, venture debt and other structured financings that look less like classic venture investing and more like balance-sheet engineering. The immediate reason is visible in the numbers: after the pandemic-era boom, biopharma venture funding fell to $18.4 billion across 481 deals in 2023 from $24.5 billion across 559 deals in 2022, while completed biotech IPO proceeds dropped to $4.4 billion in 2023 from $30.8 billion in 2020. The deeper question is more consequential: if biotech capital increasingly behaves like bank capital, who ultimately bears the risk that venture investors once claimed as their own?
The answer matters beyond the private-market jargon. When the IPO market shuts, biotech does not stop needing money; laboratories still burn cash, clinical trials still need to enroll patients and regulatory milestones still arrive on schedule. But the form of capital begins to change. Industry deal data show that eight completed biotech IPOs raised $3.72 billion in the first quarter of 2024, compared with $621 million in the fourth quarter of 2023, a sharp rebound that suggested risk appetite could return. Even so, that reopening did not restore the old bargain in full. Once the public-market exit window became less reliable, capital providers had an incentive to seek more protected return streams, and company boards had a reason to accept them.
The result is a sector increasingly funding uncertainty by slicing up its future economics before uncertainty has been resolved. Royalty Pharma, one of the clearest public markers of that model, reported Portfolio Receipts of $3.049 billion in 2023 and announced transactions of up to $4.0 billion that year, underscoring the scale already achieved by the market for monetizing future biopharma revenues. EY said in its 2026 biotech industry outlook that biotech financing reached $68.5 billion in 2025, up 11% from 2024, even as companies faced financing pressure and turned to synthetic royalty agreements and other innovative contract structures. Capital did not disappear. It changed shape.
That distinction is the story. The shape of capital determines what gets developed, which management teams keep strategic flexibility, how public investors inherit risk and, eventually, what kind of cost burden is embedded in the drug-development system. The strongest argument for structured financing is that it keeps science alive through a weak cycle. The strongest argument against it is that it raises the sector’s hidden cost of capital and biases funding toward assets that can satisfy financiers’ demand for collateral, milestones or nearer-term revenue visibility. Both statements can be true at once. The short-term move toward banker-like venture behavior is cyclical. The durable expansion of royalty, debt and hybrid capital into biotech looks increasingly structural.
What Changed: The IPO Window Shut, and Venture Capital Stopped Acting Like Pure Equity
The first-order explanation is simple. Biotech’s classic venture model depends on a chain of belief: private investors fund years of clinical burn because either the public market or a strategic buyer will eventually pay for the option value embedded in the pipeline. When public multiples were rich in 2020 and 2021, that chain looked stable. Investors could tolerate scientific uncertainty because market liquidity shortened the time between private funding and monetization. When that exit path narrowed, the same uncertainty started to look less like venture risk and more like unsecured exposure.
That is why the sector’s financing toolkit changed so quickly after the boom. Fewer IPOs meant fewer mark-to-market validations for private rounds. Lower public valuations meant a late-stage private investor could no longer assume that a crossover round would be refinanced smoothly in the public market. Higher rates compounded the problem by lifting the return hurdle for all long-duration assets, and few assets are more long-duration than a pre-revenue biotechnology company that may not have pivotal data for several years. If money itself became more expensive, so did scientific patience.
The evidence sits in both volume and structure. The fall in biopharma venture funding from $24.5 billion in 2022 to $18.4 billion in 2023 did not merely mean less cash. It meant more bargaining power for the capital that remained available. Investors and specialist financiers could demand tranched funding tied to clinical or regulatory milestones, preference stacks that insulated them from downside, royalty claims on future products, or hybrid structures that mixed equity exposure with contractual economics. The cash still arrived, but it arrived with terms that narrowed the company’s strategic freedom.
This is the point that is often flattened into a moral complaint about aggressive financiers. The mechanism is more mechanical than moral. When exit liquidity is abundant, venture capital can afford to price upside more aggressively than protection. When liquidity is scarce, it starts pricing protection first. In that sense, the banker analogy is less an insult than a description of the sector’s changing optimization function. Bankers look for security, seniority and visibility of repayment. A growing share of biotech capital now does too.
The cyclical element should not be dismissed. Part of what looks like a philosophical transformation is exactly the behavior one would expect after a market shock. Industry IPO data showing $3.72 billion raised across eight completed biotech offerings in the first quarter of 2024, after just $621 million in the fourth quarter of 2023, suggest that some risk appetite did return as issuance windows reopened. If that reopening broadens and persists, plain equity can regain ground. A financing market built under stress often softens when stress recedes.
But cycles alone do not explain why structured capital may remain central even after markets normalize. Once investors build expertise in royalties, synthetic royalties, asset-backed drug financing and downside-protected venture structures, those tools do not vanish with the next rally. Financial innovation, once proven, tends to persist because it allows capital providers to tailor risk rather than simply absorb it. That persistence is what turns a cyclical adaptation into a possible structural shift.
The public proof of that persistence is already visible in adjacent markets. Royalty Pharma’s 2023 Portfolio Receipts of $3.049 billion show that future biopharma cash flows can be packaged, priced and sold at scale. EY’s observation that companies are using synthetic royalty agreements and innovative contracting structures underlines that this is no longer a niche workaround reserved for unusual situations. It is becoming part of the standard financing menu.
"We are well positioned to continue providing customized funding solutions to our partners," Royalty Pharma Chief Executive Pablo Legorreta said in the company’s February 15, 2024 results statement.
That phrasing is revealing because it frames financing not as passive backing of discovery but as a product. Customized funding solutions are valuable in a drought. They are also a reminder that capital is no longer merely buying equity optionality. It is designing claims on future outcomes.
The Second-Order Problem: Structured Capital Can Preserve Companies While Making the System More Expensive
The obvious argument in favor of banker-like biotech financing is that it prevents forced liquidations and punitive down rounds. That is the first-order effect, and it matters. A company with credible science but poor market timing may survive because it can sell a slice of future royalties, borrow against expected milestones or accept a tranched structure that reduces immediate dilution. In a sector where clinical timelines rarely align with capital-market moods, that flexibility has real value.
The less obvious effect is that survival can come at the price of cumulative economic encumbrance. If a company funds itself by promising future royalties, adding senior claims, or layering complex preferences onto the cap table, the pipeline may look financed while the underlying economics become less attractive to future shareholders or acquirers. The science does not get worse; the claim stack above it gets thicker.
That is where the banker analogy becomes more than rhetoric. Banks do not generally seek the full upside of a borrower’s business; they seek contractual rights that protect principal and generate predictable returns. When venture investors and specialist financiers move toward that posture, they alter the risk distribution inside biotech. Scientific risk remains. Commercial risk remains. But a larger share of financing risk gets shifted forward onto whoever comes later: the public shareholder who buys the IPO, the acquirer who must work around royalty burdens, the management team that loses strategic freedom, or the patients whose therapies are deprioritized because they do not fit a financeable template.
This is the second-order issue that is still underappreciated. Structured financing can lower near-term funding risk for the company while raising the system-wide cost of capital for the industry. The more future economics are presold, the more new investors demand compensation for coming in behind those claims. That, in turn, can favor programs with cleaner, shorter or more legible cash-flow paths over messier science. Rare-disease assets with clearer pricing power or nearer regulatory milestones may finance more easily than broader, long-dated or scientifically complex programs whose payoff is harder to contract around. The financing market begins to select not just companies, but scientific shapes.
That selection effect matters because biotech has never been a neutral capital-allocation machine. Even in boom periods, it favored fashionable modalities, star syndicates and companies able to tell a clean story to crossover funds. Structured finance can intensify that bias by making it rational to fund assets that can support contract design rather than assets that merely maximize long-run medical value. A milestone-based lender or royalty buyer may prefer visibility over optionality. From a portfolio-construction standpoint, that is prudent. From an innovation-system standpoint, it can narrow the set of experiments society is willing to bankroll.
There is another transmission channel: signaling. A company that avoids a punitive down round through structured financing may preserve headline valuation or avoid public embarrassment, but the avoidance can blur price discovery. Public investors often assume private backers still bear clean equity risk. In reality, those backers may have improved their position through preferences, warrants, ratchets, royalty claims or debt covenants that ordinary shareholders do not share. The appearance of alignment can outlast the substance of alignment.
That matters most when the market reopens. If the IPO window improves, companies that survived the drought may come public with more complex economic baggage than their surface story suggests. The risk is not that every structured deal is predatory. It is that the sector as a whole becomes harder to underwrite from the outside. Traditional biotech equity analysis already requires judgment on clinical probability, regulatory timing, competitive intensity and cash burn. Add bespoke financing claims, and the task becomes materially harder. Complexity acts as a financing subsidy in the private market and a valuation discount in the public one.
In that sense, the industry may be replaying a familiar market pattern on a smaller and more specialized scale: a stress-era innovation solves an immediate funding problem and then leaves the system more opaque. The analogy is not to a banking crisis; biotech is too small for that. The analogy is to how protected capital structures migrate risk rather than remove it. The bill is still paid. The real question is by whom and when.
Is This Cyclical or Structural? The Answer Changes by Horizon
The easiest analytical mistake is to force a single verdict. The funding shift is partly cyclical and partly structural, and the balance changes by time horizon. In the short term, the move toward banker-like venture behavior is a cyclical response to scarcer exits, tighter monetary conditions and the valuation reset that followed the 2021 peak. Those pressures are not permanent. If the IPO market broadens, acquisitions accelerate and generalist capital re-enters biotech, some of the most punitive structures should lose pricing power.
History supports at least part of that mean-reversion case. Biotech financing has repeatedly loosened when data-rich risk appetite returns, especially after a handful of successful listings re-establish price discovery. The rebound in first-quarter 2024 IPO proceeds after the late-2023 trough fits that pattern, even if it was narrow. Markets that freeze can thaw.
Yet the longer-term shift looks more structural for three reasons. First, specialist capital pools dedicated to royalties and hybrid funding now operate at meaningful scale. A market with publicly visible players reporting billions of dollars in receipts and transactions is no longer experimental. Second, boards and investors have learned that different pieces of drug economics can be separated, sold and refinanced. Once that toolkit exists, it does not disappear, especially because it can reduce dilution for insiders even if it increases complexity for later entrants. Third, the investor base itself has diversified. Biotech is no longer financed only by classic venture firms and public equity investors; it increasingly sits at the intersection of venture, private credit, royalty finance and crossover capital. Market-structure shifts of that kind tend to persist because they create new specialists with permanent incentives to stay.
That is why the structural call should be made carefully but made nonetheless. The old model of biotech venture capital as almost pure equity risk capital is unlikely to return in full. What may return is a more generous mix of that capital during favorable windows. What is less likely to disappear is the availability—and therefore the bargaining power—of financiers that can offer money with strings economically senior to plain common equity.
The strongest counter-thesis is that this evolution is healthy rather than dangerous. Under that view, biotech has simply matured. Drug development is expensive, timelines are long and plain venture equity was always an inefficient way to fund every stage of the process. More instruments should mean better matching between asset type and funding source, fewer promising programs killed by temporary market closures and, over time, a more resilient innovation ecosystem. If royalties or synthetic royalties fund companies that would otherwise shut down, the argument goes, then the system has gained flexibility rather than lost virtue.
That is a real challenge to the skeptical reading, and it cannot be waved away. In many cases, structured financing will be exactly the right answer. A company with a de-risked commercial asset may rationally sell part of a royalty stream rather than issue discounted equity. A late-stage platform company may sensibly combine debt, equity and milestone funding to bridge to data. A broader financing menu can indeed make the system more durable through cyclical shocks.
But that counter-thesis weakens if complexity rises faster than transparency or if financing claims begin to shape scientific choice. The signal that would falsify the more skeptical view is concrete: if the next sustained biotech reopening produces cleaner cap tables, wider access to plain equity funding and no valuation discount for companies that used structured capital through the downturn, then today’s concerns will have been overstated. Put differently, if public investors prove willing to fund those companies at strong valuations without demanding compensation for embedded royalty, debt or preference complexity, then the market will have shown that hybrid structures truly reduced rather than merely redistributed risk.
If, however, reopened public markets continue to favor only the cleanest stories while encumbered companies trade at a discount or are pushed into asset sales, the structural-warning thesis will look stronger. That would mean the sector did not merely borrow against a bad cycle. It permanently increased the number of claims standing between scientific success and shareholder value realization.
Who Pays the Price if Venture Capital Turns Into Banking Capital?
The answer depends on time horizon. In the short term, banker-like capital can be a relief valve. It may preserve jobs, keep trials running and give management teams time to reach clinical catalysts. That is why the model has grown: it solves a real problem. For private insiders, it can also reduce the pain of outright down rounds by sourcing cash from structures that protect valuation optics.
Over the medium term, the burden shifts. Public-market investors may inherit companies whose science is intact but whose economics are partly spoken for. Strategic acquirers may pay less for assets wrapped in royalty obligations or layered with financing preferences. Smaller biotech companies may devote more management time to financing design and covenant navigation rather than research execution. And if investors learn to underwrite those frictions in advance, the result is a higher required return on new biotech equity issues.
Over the long term, the broadest payer may be the innovation system itself. If structured capital consistently favors nearer-term, more easily collateralized programs, the sector may underfund harder science whose social value is high but whose payoff is less convenient financially. That would not show up immediately in quarterly financing totals. It would show up slowly in pipeline composition, the concentration of capital around certain asset types and perhaps in a wider gap between what is medically valuable and what is easiest to finance.
The base case is not a collapse of biotech financing. It is a repricing of what venture means. In that base case, companies continue to raise money, but a larger share of capital comes with contractual claims on future economics. The upside case is that this proves a disciplined evolution: structured funding bridges the weak-cycle years, the IPO market normalizes and companies emerge with enough transparency that public investors accept the trade-offs. The downside case is that the sector discovers too late that it preserved enterprise life by mortgaging too much future value, leaving public investors and acquirers to discount the very assets private capital once claimed to believe in.
The catalyst list is concrete. Investors should watch whether biotech IPO issuance broadens beyond a narrow set of data-rich names; whether newly listed companies with prior royalty or hybrid structures trade differently from cleaner peers; whether royalty and synthetic-royalty markets continue to scale faster than plain equity issuance; and whether boards begin disclosing financing encumbrances more explicitly as part of the path-to-commercialization story. The clearest falsifying signal for the skeptical thesis would be a sustained reopening in which structured-finance users secure strong IPO aftermarket performance without meaningful valuation haircuts relative to peers with simpler capital structures.
As of August 14, 2026, the available industry data still point to a sector in transition rather than a sector healed. Biotech capital has not stopped funding science. It has become more determined to protect itself first. If that instinct remains a cyclical adaptation, the cost may be manageable. If it hardens into the permanent funding model, biotech may discover too late that it did not eliminate uncertainty; it merely reassigned it to whoever came after the financiers.
Explore more exclusive insights at nextfin.ai.
